TSHR in thyroid cancer: bridging biological insights to targeted strategies

QR Code

TSHR in thyroid cancer: bridging biological insights to targeted strategies

Traditionally, thyroid-stimulating hormone receptor (TSHR) has been utilized primarily to increase the efficacy of radioactive iodine therapy by promoting iodine uptake. However, the rise of personalized medicine has prompted reassessment of the potential of TSHR as a therapeutic target. Recent stud...

Full description

Saved in:

Bibliographic Details
Main Authors:	Shaojie Xu, Youyun Peng, Xingyin Li, Hanning Li, Ting Liu, Xingrui Li, Yaying Du
Format:	Article
Language:	English
Published:	Bioscientifica 2025-07-01
Series:	European Thyroid Journal
Subjects:	tshr differentiated thyroid cancer radioiodine-refractory differentiated thyroid cancer targeted strategies
Online Access:	https://etj.bioscientifica.com/view/journals/etj/14/4/ETJ-24-0369.xml
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial
by: M. S. Brose, et al.
Published: (2018-07-01)

Observation and treatment of patients with progressive metastatic differentiated thyroid cancer after establishment of radioiodine refractoriness
by: E. V. Borodavina, et al.
Published: (2024-08-01)

Experience in the use of targeted therapy in patients with radio-resistant forms of thyroid cancer in the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
by: E. B. Vasil’eva, et al.
Published: (2018-04-01)

Clinical outcome and influencing factors of differentiated thyroid cancer patients with radioiodine-refractory lung metastasis
by: Congcong Wang, et al.
Published: (2025-08-01)

Prolonged duration of response in lenvatinib responders with thyroid cancer (Russian translation)
by: A. G. Gianoukakis, et al.
Published: (2018-11-01)

Selpercatinib in the treatment of medullary and radioiodine-refractory differentiated thyroid cancer with RET mutation (literature review)
by: E. V. Borodavina, et al.
Published: (2025-03-01)

Guidelines for radioiodine therapy in differentiated thyroid cancer and post-therapeutic follow-up
by: A. Yu. Shurinov, et al.
Published: (2024-06-01)

Historical aspects and modern concepts in the treatment of patients with differentiated thyroid cancer, refractory to radioactive iodine therapy
by: E. V. Borodavina, et al.
Published: (2022-02-01)

Neoadjuvant target therapy of differentiated thyroid cancer (clinical observation)
by: P. A. Isaev, et al.
Published: (2017-04-01)

Lenvatinib in advanced radioiodine-refractory differentiated thyroid cancer: what’s new?
by: E. V. Borodavina, et al.
Published: (2024-12-01)

Brain metastasis from differentiated thyroid carcinoma responding to radioiodine therapy
by: Leo Hashimoto, et al.
Published: (2025-07-01)

Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation
by: E. V. Borodavina, et al.
Published: (2020-04-01)

Survival analysis of patients with advanced metastatic differentiated thyroid cancer
by: E. V. Borodavina, et al.
Published: (2022-08-01)

Advanced metastatic radioiodine refractory differentiated thyroid cancer: current treatment and dynamic surveillance issues
by: E. V. Borodavina, et al.
Published: (2025-03-01)

Personalized therapy with lenvatinib for progressive radioiodine refractory differentiated thyroid cancer in routine clinical practice
by: P. O. Rumyantsev, et al.
Published: (2021-11-01)

Predictive factors of radioiodine ablation success: results from a MEDIRAD prospective clinical study for thyroid cancer
by: Jan Taprogge, et al.
Published: (2025-07-01)

Clinical experience in using lenvatinib in patients with progressive, radioactive iodine-refractory differentiated thyroid cancer
by: P. A. Isaev, et al.
Published: (2016-06-01)

CRITERIA OF WELL-DIFFERENTIATED THYROID CARCINOMA RESISTANCE TO RADIOIODINE THERAPY
by: P. O. Rumyantsev, et al.
Published: (2015-04-01)

The utility of quantitative 18F-FDG PET/CT-derived parameters as prognostic factors for predicting overall survival in radioiodine-refractory differentiated thyroid cancer
by: Mai Son, et al.
Published: (2025-07-01)

Incidence of Adverse Events Related to Therapies with sodium iodine (131I): Contribution to the Pharmacovigilance in Brazil
by: Jaqueline Cardena Fernandes, et al.
Published: (2024-09-01)

RADIOIODINE THERAPY OF PAPILLARY THYROID CANCER, COMPLICATED BY A RADIAL MYELITIS. CLINICAL CASE
by: L. M. Farkhutdinova
Published: (2018-06-01)

Errors in the treatment of highly differentiated thyroid cancer as a multidisciplinary problem
by: N. I. Volkova, et al.
Published: (2021-07-01)

New-generation mutitargeted tyrosine kinase inhibitors in the treatment of radioactive iodine-refractory differentiated thyroid cancer
by: A. M. Mudunov
Published: (2015-06-01)

Place of istmusectomy in thyroid tumors management: experience of National Medical Research Center of Endocrinology
by: P. A. Nikiforovich, et al.
Published: (2025-03-01)

TARGET THERAPY OF HIGH DIFFERENTIATED CARCINOMA RESISTANT TO RADIOIOD THERAPY (REVIEW OF LITERATURE)
by: S. V. Vasilkov, et al.
Published: (2017-11-01)

Evaluation of biokinetics and dosimetry in [131I]-NaI therapies: whole-body images quantification versus lower limb region
by: Bianca Lemos Lima, et al.
Published: (2020-06-01)

Diagnostic score of malignancy risk in the people having a node in thyroid gland (Petrov Thyroid Cancer Score, PTCS)
by: A. M. Belyaev, et al.
Published: (2018-04-01)

The Impact of Radioiodine (131I) Therapy of Thyroid Disease on Salivary Glands Function and Inflammation: A Comprehensive Review
by: Pietro Bellini, et al.
Published: (2025-06-01)

Value of 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography in staging of patients with differentiated thyroid cancer after thyroidectomy during the first course of radioiodine therapy
by: T. M. Geliashvili, et al.
Published: (2021-01-01)

Algorithm of stepwise medical rehabilitation of patients with differentiated thyroid cancer
by: T. I. Grushina, et al.
Published: (2021-04-01)

Challenges of Diagnosis and Treatment Choice in Riedel‘s Fibrosing Thyroiditis: Clinical Case Examples
by: M. G. Davydovich, et al.
Published: (2022-06-01)

“Watch and wait” approach in the treatment of advanced radioiodine refractory differentiated thyroid cancer: a study of barriers and drivers of use
by: E. V. Borodavina, et al.
Published: (2024-04-01)

THE ROLE OF BRAF MUTATION STATUS IN SURGICAL TREATMENT OF WELL-DIFFERENTIATED THYROID CANCER
by: A. P. Polyakov, et al.
Published: (2017-04-01)

The use of 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography in patients with differentiated thyroid cancer after initial treatment
by: T. M. Geliashvili, et al.
Published: (2017-04-01)

REFRACTORY OF WELL-DIFFERENTIATED THYROID CANCER TO THE TREATMENT WITH RADIOACTIVE IODINE
by: P. O. Rumyantsev
Published: (2015-04-01)

The Initial Risk Stratification System for Differentiated Thyroid Cancer: Key Updates in the 2024 Korean Thyroid Association Guideline
by: Shinje Moon, et al.
Published: (2025-06-01)

Exophytic pancreatic lymphoepithelial cyst incidentally detected in a differentiated thyroid cancer patient on whole-body I-131 scan: a case report
by: Takahiro Murokawa, et al.
Published: (2022-02-01)

Clinical experience in the neoadjuvant treatment of unresectable differentiated thyroid cancer with the lenvatinib
by: E. B. Vasilyeva, et al.
Published: (2024-06-01)

GENERAL ASPECTS OF THE DIAGNOSIS AND TREATMENT OF LOCALLY ADVANCED THYROID CANCER
by: L. P. Yakovleva, et al.
Published: (2015-04-01)

Possible risk factors for thyroid cancer (on the example of Altai Territory residents)
by: I. M. Zakharova, et al.
Published: (2025-03-01)